Unknown

Dataset Information

0

NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.


ABSTRACT:

Background

Our preclinical work revealed tumour hypoxia induces homologous recombination deficiency (HRD), increasing sensitivity to Poly (ADP-ribose) polymerase inhibitors. We aimed to induce tumour hypoxia with ramucirumab thereby sensitising tumours to olaparib.

Patients and methods

This multi-institution single-arm Phase 1/2 trial enrolled patients with metastatic gastroesophageal adenocarcinoma refractory to ≥1 systemic treatment. In dose escalation, olaparib was evaluated at escalating dose levels with ramucirumab 8 mg/kg day 1 in 14-day cycles. The primary endpoint of Phase 1 was the recommended Phase 2 dose (RP2D), and in Phase 2 the primary endpoint was the overall response rate (ORR).

Results

Fifty-one patients received ramucirumab and olaparib. The RP2D was olaparib 300 mg twice daily with ramucirumab 8 mg/kg. In evaluable patients at the RP2D the ORR was 6/43 (14%) (95% CI 4.7-25.6). The median progression-free survival (PFS) was 2.8 months (95% CI 2.3-4.2) and median overall survival (OS) was 7.3 months (95% CI 5.7-13.0). Non-statistically significant improvements in PFS and OS were observed for patients with tumours with mutations in HRD genes.

Conclusions

Olaparib and ramucirumab is well-tolerated with efficacy that exceeds historical controls with ramucirumab single agent for gastric cancer in a heavily pre-treated patient population.

SUBMITTER: Cecchini M 

PROVIDER: S-EPMC10844282 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>Our preclinical work revealed tumour hypoxia induces homologous recombination deficiency (HRD), increasing sensitivity to Poly (ADP-ribose) polymerase inhibitors. We aimed to induce tumour hypoxia with ramucirumab thereby sensitising tumours to olaparib.<h4>Patients and methods</h4>This multi-institution single-arm Phase 1/2 trial enrolled patients with metastatic gastroesophageal adenocarcinoma refractory to ≥1 systemic treatment. In dose escalation, olaparib was evaluated at  ...[more]

Similar Datasets

| S-EPMC4803452 | biostudies-literature
| S-EPMC9524015 | biostudies-literature
| S-EPMC4622287 | biostudies-literature
| S-EPMC4966750 | biostudies-literature
| S-EPMC6527138 | biostudies-literature
| S-EPMC5827797 | biostudies-literature
| S-EPMC10403909 | biostudies-literature
| S-EPMC10754747 | biostudies-literature
| S-EPMC2903332 | biostudies-literature
| S-EPMC6324629 | biostudies-literature